Retatrutide vs Semaglutide vs Tirzepatide: Which Wins for Body Recomposition?
Three peptides. Three different receptor profiles. One definitive question for the aesthetics community: which delivers the best fat loss with the least muscle sacrifice? We stack the clinical trial data side by side.
Research Purposes Only. Retatrutide, Semaglutide, and Tirzepatide discussed here are research peptides/compounds. This content is for educational and informational purposes only and does not constitute medical advice. All compounds referenced are for in-vitro research use. Consult a licensed healthcare professional before beginning any protocol.
All content is for educational and research purposes only. Peptides discussed are research compounds not approved by the FDA for human use. Nothing on this page constitutes medical advice.
Clinical Trial Weight Loss at a Glance
-24.2%
Retatrutide
Phase 2 · 48 weeks
-22.5%
Tirzepatide
SURMOUNT-1 · 72 weeks
-15%
Semaglutide
STEP-1 · 68 weeks
3 vs 2 vs 1
Receptors Targeted
Reta · Tirz · Sema
The GLP Receptor Landscape
GLP-1, GIP, and Glucagon are three incretin and metabolic hormones that govern energy balance, appetite, and fat oxidation through distinct but overlapping pathways. The history of GLP-class compounds is one of progressive receptor expansion — each generation adds another target and, accordingly, another vector of metabolic pressure.
Semaglutide is first generation: pure GLP-1 agonism. Tirzepatide added the GIP receptor to the equation, unlocking synergistic effects that no single-target compound could match. Retatrutide goes one step further, stacking Glucagon receptor activation on top of both — triggering direct thermogenesis in brown adipose tissue in a way neither predecessor can achieve.
For the looksmaxxing community, this matters because the goal is not simply weight loss — it is body recomposition: maximum fat oxidation with minimal lean mass catabolism. The glucagon receptor arm of Retatrutide may be the key differentiator here.
Mechanism Comparison
Semaglutide
Ozempic / Wegovy
- GLP-1 receptor agonist only
- Appetite suppression via hypothalamus
- ~15% weight loss (STEP-1, 68 wks)
- FDA approved (Ozempic / Wegovy)
- SELECT trial: 20% MACE reduction
-15%
Avg body weight
Tirzepatide
Mounjaro / Zepbound
- GLP-1 + GIP dual agonist
- Synergistic appetite + insulin action
- ~22.5% weight loss (SURMOUNT-1, 72 wks)
- FDA approved (Mounjaro / Zepbound)
- 47% greater loss vs sema (SURMOUNT-5)
-22.5%
Avg body weight
Retatrutide
TRIUMPH Trial (Phase 3 ongoing)
- GLP-1 + GIP + Glucagon triple agonist
- Appetite + insulin + thermogenesis
- ~24.2% weight loss (Phase 2, 48 wks)
- Phase 3 TRIUMPH trial ongoing
- Highest fat-loss ceiling of any class
-24.2%
Avg body weight (Phase 2)
The Glucagon Advantage: Why the Third Receptor Matters
The leap from dual to triple agonism is not incremental — it is mechanistically distinct. Glucagon receptor (GCGR) activation drives hepatic fat oxidation and brown adipose tissue (BAT) thermogenesis through pathways that GLP-1 and GIP simply do not access. In animal models, glucagon co-agonism increases whole-body energy expenditure by 10–20% beyond appetite-driven caloric restriction alone.
BAT Thermogenesis
Glucagon receptor stimulation activates brown adipose tissue, increasing basal metabolic rate independent of caloric intake. This is fat burned as heat — not dependent on creating a caloric deficit.
Hepatic Fat Oxidation
GCGR activation in the liver increases fatty acid beta-oxidation and reduces de novo lipogenesis. The result: the liver preferentially burns fat instead of storing it, accelerating visceral fat reduction.
Preserved Lean Mass
GIP receptor activation has been associated with improved muscle uptake of nutrients. Combined with glucagon-driven preferential fat catabolism, the triple agonist profile theoretically spares lean tissue more than GLP-1 alone.
In practical terms: semaglutide produces weight loss primarily by making you eat less. Tirzepatide does the same, more powerfully, and also improves insulin-mediated nutrient partitioning. Retatrutide does all of that and directly increases the rate at which stored fat is burned — making it the most comprehensive tool in the GLP class for body recomposition.
Body Recomposition for Aesthetics: What the Data Means
The looksmaxxing community's goal differs from the clinical obesity-treatment paradigm. The target is not just a lower number on a scale — it is a higher fat-free mass index, sharper facial definition, and visible muscle at a lower body fat percentage. This reframes the peptide comparison.
The Lean Mass Problem with GLP-1 Alone
Pure GLP-1 agonism (semaglutide) produces aggressive weight loss, but DEXA analyses from STEP trials show approximately 40% of total weight loss can come from lean mass in some participants. For someone optimizing for aesthetics, losing significant muscle while cutting fat is a poor trade. Tirzepatide shows somewhat better lean mass preservation, and Retatrutide's glucagon arm may further shift the ratio toward fat oxidation — though head-to-head DEXA data comparing all three remains limited.
Retatrutide's Advantage for Aesthetics
The glucagon receptor's role in promoting hepatic fat oxidation and BAT thermogenesis means energy expenditure increases through additional pathways beyond appetite suppression. Rather than losing weight by eating dramatically less (which risks muscle catabolism from low protein intake), Retatrutide creates a thermogenic environment where fat is preferentially mobilized. Paired with adequate protein and resistance training, this is an optimal recomposition profile.
Clinical Trial Data: Deep Dive
| Trial | n | Duration | Weight Loss |
|---|---|---|---|
| STEP 1 | 1,961 | 68 wks | -14.9% |
| STEP 2 (T2D) | 1,210 | 68 wks | -9.6% |
| STEP 3 (+ behavioral) | 611 | 68 wks | -16.0% |
| STEP 5 (2 year) | 304 | 104 wks | -15.2% |
Key insight: Semaglutide is highly consistent across trial populations — the ~15% average holds up across multiple study designs. Its cardiovascular data (SELECT trial, n=17,604) is the most mature of the three, showing a 20% reduction in MACE.
| Trial | n | Duration | Best Result |
|---|---|---|---|
| SURMOUNT-1 | 2,539 | 72 wks | -22.5% (15mg) |
| SURMOUNT-2 (T2D) | 938 | 72 wks | -15.7% (15mg) |
| SURMOUNT-4 (withdrawal) | 670 | 88 wks | +14% regain off drug |
| SURMOUNT-5 (vs sema) | 751 | 72 wks | -20.2% vs -13.7% |
SURMOUNT-1 highlight: at 15mg, 39.7% of participants achieved ≥25% body weight loss — a threshold previously associated only with bariatric surgery outcomes.
| Study | n | Duration | Result |
|---|---|---|---|
| Phase 2 (NEJM 2023) | 338 | 48 wks | -24.2% (12mg) |
| Phase 2 — 4mg arm | 338 | 48 wks | -17.5% |
| Phase 2 — 8mg arm | 338 | 48 wks | -22.8% |
| TRIUMPH Phase 3 | ~2,000+ | Ongoing | Results pending |
Phase 2 data (NEJM 2023, n=338, 48 weeks) is the most rigorous published evidence to date. At the 12mg dose, -24.2% total body weight was achieved — and the trajectory showed no plateau at week 48, suggesting Phase 3 numbers may exceed this.
Source Retatrutide for Your Research
Research-grade Retatrutide 15mg — >98% purity, third-party COA, shipped discreetly. Available now from our trusted supplier.
Side Effect Comparison
| Side Effect | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Nausea | Moderate (16–44%) | Moderate (12–33%) | Higher (25–45%) |
| Vomiting | Moderate | Lower | Moderate–High |
| Diarrhea | Common | Common | Common |
| GI Discontinuation | 5.6% (SURMOUNT-5) | 2.7% (SURMOUNT-5) | ~10–18% (Phase 2) |
| Heart Rate ↑ | Mild | Mild | Higher (GCGR effect) |
| Cardiovascular Data | Mature (SELECT) | Emerging | Early-stage |
| Gallbladder Events | Low risk | Low risk | Under investigation |
Retatrutide's higher GI burden is attributable to the glucagon receptor arm. The Phase 2 protocol used a slow titration to manage this — starting at 0.5mg and titrating over 24 weeks. A slowtitration protocol substantially mitigates these effects.
Cost & Access Comparison
Semaglutide
~$1,300/mo
Wegovy list price (US, without insurance)
- FDA approved — prescription required
- Often covered for T2D, not always obesity
- Generic compound research vials: much lower cost
Tirzepatide
~$1,060/mo
Zepbound list price (US, without insurance)
- FDA approved — prescription required
- Manufacturer savings card available
- Research grade: more accessible pricing
Retatrutide
Research Grade
Not FDA approved — research use
- No prescription required for research
- Significantly lower cost per mg vs branded
- Available now from ClavTides supplier
- Best cost-per-result in its class
Research-grade compounds are sold for laboratory and in-vitro research purposes only. Pricing reflects research supplier market rates and is subject to change.
Which to Choose: The Verdict for Aesthetics & Looksmaxxing
For Body Recomposition: Retatrutide Wins
Triple agonism + thermogenesis + highest weight-loss ceiling
If the goal is maximum fat reduction with the best possible lean-mass retention — the definition of body recomposition — Retatrutide's triple agonism makes it the frontrunner. The glucagon receptor adds a dimension that GLP-1 and GIP simply cannot replicate: direct thermogenic fat catabolism.
Maximum Fat Loss
-24.2% Phase 2 data — highest published number in the GLP class.
Thermogenic Advantage
Glucagon receptor drives BAT activation — fat burned as heat, not just from eating less.
Accessible Research Cost
Research-grade supply available now — no prescription, lower cost than branded alternatives.
Choose Tirzepatide if...
- You want the best-studied dual agonist with FDA approval
- GI tolerance is a primary concern
- You have a prescription and insurance coverage
- SURMOUNT cardiovascular data matters for your research
Choose Semaglutide if...
- Pure GLP-1 pharmacology is the research focus
- Cardiovascular outcomes are a priority (SELECT data)
- Oral administration is desired (Rybelsus)
- Longest longitudinal study data (STEP 5, 2 years)
Why We Pair Retatrutide with BPC-157
Aggressive fat loss — especially at the weight loss percentages Retatrutide enables — creates recovery demands. Rapid reduction in body weight, combined with any resistance training program, puts joints, tendons, and connective tissue under elevated stress. This is why the Clavicular stack was built around a core principle: recomposition should not cost recovery.
Retatrutide — The Engine
- Triple agonism drives maximum fat catabolism
- BAT thermogenesis elevates resting energy expenditure
- GIP arm supports insulin-mediated nutrient delivery to muscle
- Weekly subcutaneous administration
BPC-157 — The Recovery Layer
- Supports tendon and ligament repair signaling
- Upregulates growth hormone receptor expression
- Anti-inflammatory at sites of mechanical stress
- Daily subcutaneous or oral administration
The combination creates a complete recomposition environment: the thermogenic and appetite-regulating power of Retatrutide accelerates fat loss, while BPC-157's recovery signaling keeps training output high and injury risk low throughout the cut. This is the Clavicular philosophy — maximum aesthetic outcome with structural integrity maintained.
Go Deeper
The Clavicular Peptide Stack: Full Protocol & Rationale
Complete breakdown of how Retatrutide, BPC-157, and supporting peptides work together for maximum recomposition.
Read article Dosing GuideRetatrutide Dosing Guide 2026: Starting Dose & Titration
Phase 2 trial-derived dosing schedule, titration protocol, and how to structure a 24-week research cycle.
Read articleThe Triple Agonist is Available Now
Research-grade Retatrutide 15mg — >98% purity, third-party COA, discreet shipping. The highest-ceiling fat-loss compound in the GLP class.
Related Research Guides
- Weight Loss
Retatrutide: Full Clinical Breakdown
TRIUMPH program summary, evidence grades, contraindications, 4mg maintenance dose research.
- GLP-1 Research
Semaglutide vs Tirzepatide: Head-to-Head Data
SURMOUNT-5 results, SELECT CV outcomes, and the GIP receptor mechanism explained.
- Peptide Stacking
Complete Guide to Peptide Stacking
How to combine GLP-1 class peptides with other research compounds.
- Protocol Research
Clavicular Retatrutide Protocol Breakdown
Real-world research protocol documentation with retatrutide at the center.